Berta Hernández

Functional systemic <scp>CD</scp> 4 immunity is required for clinical responses to <scp>PD</scp> ‐L1/ <scp>PD</scp> ‐1 blockade therapy

Miren Zuazo, Hugo Arasanz, G. Fernández-Hinojal et al. · EMBO Molecular Medicine · 2019 · 211 citations · Full text

Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics

Hugo Arasanz, Miren Zuazo, Ana Bocanegra et al. · Cancers · 2020 · 65 citations · Full text

Determinants of patient satisfaction with care in a Spanish oncology Day Hospital and its relationship with quality of life

Juan Ignacio Arrarás, José Juan Illarramendi, A. Viúdez et al. · Psycho-Oncology · 2013 · 43 citations

Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor–positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment

Mariano Provencio, Roberto Serna‐Blasco, V. Blázquez Calvo et al. · European Journal of Cancer · 2021 · 30 citations · Full text

EPB41L3, TSP-1 and RASSF2 as new clinically relevant prognostic biomarkers in diffuse gliomas

Noemí Pérez‐Janices, Idoia Blanco‐Luquin, Maria Teresa Tuñón et al. · Oncotarget · 2015 · 27 citations · Full text